Evidence map›Paper›PMID 30995314›Full record

ArticleInvestigative ophthalmology & visual science2019

Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.

Yan Hu, Arturo O Barron, Sofya Gindina, Sandeep Kumar, Shravan Chintala, Ashima Nayyar, John Danias

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Glucocorticoid-Induced Ocular Hypertension and Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yan HuDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
Arturo O BarronDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
Sofya GindinaDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
Sandeep KumarDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
Shravan ChintalaInstitute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States.
Ashima NayyarDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
John DaniasDepartment of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York, United States.
SUNY Downstate Health Sciences University · USUniversity of Southern California · US

Funding

tPA mechanisms in outflow facility regulation in glaucomaR01EY025543 · NEI · SUNY DOWNSTATE MEDICAL CENTER · PI DANIAS, JOHN · 2015 to 2019
$1.8M
NEI NIH HHS R01 EY025543
6 · The paper itself

Abstract

Purpose: To understand the role and further dissect pathways downstream of tissue plasminogen activator (tPA) and the fibrinolytic pathway in modulating outflow facility. Methods: Outflow facility of tissue plasminogen activator (Plat) knockout (KO) mice was determined and compared to that of wild-type (WT) littermates. Gene expression of urokinase plasminogen activator (Plau), plasminogen activator inhibitor (Pai-1), plasminogen (Plg), and matrix metalloproteinases (Mmp-2, -9, and -13) was measured in angle tissues. Expression of the same genes and outflow facility were measured in KO and WT mice treated with triamcinolone acetonide (TA). Amiloride was used to inhibit urokinase plasminogen activator (uPA) in Plat KO mice, and outflow facility was measured. Results: Plat deletion resulted in outflow facility reduction and decreased Mmp-9 expression in angle tissues. Plasminogen expression was undetectable in both KO and WT mice. TA led to further reduction in outflow facility and decreases in expression of Plau and Mmp-13 in plat KO mice. Amiloride inhibition of uPA activity prevented the TA-induced outflow facility reduction in Plat KO mice. Conclusions: tPA deficiency reduced outflow facility in mice and was associated with reduced MMP expression. The mechanism of action of tPA is unlikely to involve plasminogen activation. tPA is not the only mediator of TA-induced outflow facility change, as TA caused reduction in outflow facility of Plat KO mice. uPA did not substitute for tPA in outflow facility regulation but abrogated the effect of TA in the absence of tPA, suggesting a complex role of components of the fibrinolytic system in outflow regulation.

Indexed as

AmilorideAnimalsDiureticsFibrinolysisGene Expression RegulationGlucocorticoidsInjections, IntraocularIntraocular PressureMatrix Metalloproteinase 13Matrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMice, Inbred C57BLMice, KnockoutPlasminogenPlasminogen Activator Inhibitor 1AmilorideDiureticsGlucocorticoidsMatrix Metalloproteinase 13Matrix Metalloproteinase 2Matrix Metalloproteinase 9Mmp13 protein, mouseMmp2 protein, mouseMmp9 protein, mousePlasminogenPlasminogen Activator Inhibitor 1Tissue Plasminogen ActivatorTriamcinolone AcetonideUrokinase-Type Plasminogen Activator

Identifiers

PMID30995314
PMCPMC6892382
OpenAlexW2940152388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.